Medicines Development for Global Health (MDGH) is a global not-for-profit company dedicated to the development of medicines and vaccines for neglected diseases.
MDGH is working to address global health inequities by researching, developing and delivering new and improved medicines to those people who need them the most. Many neglected tropical diseases (NTDs) are primarily endemic in low- to middle-income countries where people and communities are disproportionally disadvantaged by the traditional consideration of market returns on medicines development. The innovative MDGH not-for-profit model is based on pubic health needs in these affected areas rather than commercial opportunity.
Notably, MDGH became the first independent not-for-profit company to achieve FDA approval for a novel medicine when they registered moxidectin in 2018, the first new treatment for river blindness (onchocerciasis) in 20 years.
Visit: medicinesdevelopment.com for more information.
